Research Analysts Offer Predictions for OTLK FY2026 Earnings

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Equities researchers at Brookline Capital Management lowered their FY2026 earnings per share estimates for shares of Outlook Therapeutics in a research report issued on Tuesday, May 27th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of $0.50 for the year, down from their previous estimate of $0.54. The consensus estimate for Outlook Therapeutics' current full-year earnings is ($2.27) per share.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.15.

Several other research analysts have also commented on OTLK. Guggenheim reiterated a "buy" rating on shares of Outlook Therapeutics in a research report on Tuesday, May 20th. Ascendiant Capital Markets reduced their price objective on Outlook Therapeutics from $33.00 to $24.00 and set a "buy" rating for the company in a research report on Monday, February 24th. HC Wainwright reduced their price objective on Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, February 18th. Finally, Chardan Capital restated a "neutral" rating and set a $3.00 price objective on shares of Outlook Therapeutics in a research report on Tuesday, February 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $10.20.

Outlook Therapeutics Stock Up 2.8%

Shares of OTLK traded up $0.05 during mid-day trading on Thursday, hitting $1.85. The stock had a trading volume of 1,205,337 shares, compared to its average volume of 771,774. The company has a market cap of $62.10 million, a PE ratio of -0.25 and a beta of 0.39. The company's fifty day simple moving average is $1.48 and its two-hundred day simple moving average is $1.90. Outlook Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $9.25.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its position in Outlook Therapeutics by 1,329.6% during the 4th quarter. Rhumbline Advisers now owns 188,050 shares of the company's stock valued at $355,000 after purchasing an additional 174,896 shares during the period. Renaissance Technologies LLC bought a new stake in Outlook Therapeutics during the 4th quarter valued at $246,000. Goldman Sachs Group Inc. raised its stake in Outlook Therapeutics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after acquiring an additional 44,063 shares in the last quarter. AQR Capital Management LLC raised its stake in Outlook Therapeutics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after acquiring an additional 25,351 shares in the last quarter. Finally, Scotia Capital Inc. raised its stake in Outlook Therapeutics by 124.4% during the 4th quarter. Scotia Capital Inc. now owns 73,989 shares of the company's stock valued at $140,000 after acquiring an additional 41,023 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company's stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.